Ron Weitzman, MD, FACP

Ron Weitzman has over 25 year’s experience leading oncology clinical studies ranging from early to late-stage clinical development, including pivotal studies for cabozantanib and nilotinib that led to FDA approval. Prior to joining Osmol as Chief Medical Officer on a consulting basis, Dr. Weitzman has held leadership roles at various global biopharmaceutical companies, including Exelixis, Genentech Novartis and Lilly, and has served as a consulting CMO to various biotechnology companies for nearly a decade. Dr Weitzman is board-certified by the American Board of Internal Medicine in Medical Oncology.